Yazici H - Search Results

1

2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria sets for three types of antineutrophilic cytoplasmic antibody-associated vasculitis.

Yazici H, Tascilar K, Yazici Y. Yazici H, et al. Among authors: yazici y. Curr Opin Rheumatol. 2023 Jan 1;35(1):1-5. doi: 10.1097/BOR.0000000000000916. Epub 2022 Nov 15. Curr Opin Rheumatol. 2023. PMID: 36382396 Review.

2

Infliximab does not suppress the tuberculin skin test (purified protein derivative).

Hatemi G, Melikoglu M, Fresko I, Masatlioglu S, Tascilar K, Yazici H. Hatemi G, et al. Among authors: yazici h. J Rheumatol. 2007 Mar;34(3):474-80. Epub 2007 Feb 1. J Rheumatol. 2007. PMID: 17299840 Clinical Trial.

3

The unique features of vasculitis in Behçet's syndrome.

Melikoglu M, Kural-Seyahi E, Tascilar K, Yazici H. Melikoglu M, et al. Among authors: yazici h. Clin Rev Allergy Immunol. 2008 Oct;35(1-2):40-6. doi: 10.1007/s12016-007-8064-8. Clin Rev Allergy Immunol. 2008. PMID: 18172779 Review.

4

Increased enthesopathy among Behçet's syndrome patients with acne and arthritis: an ultrasonography study.

Hatemi G, Fresko I, Tascilar K, Yazici H. Hatemi G, et al. Among authors: yazici h. Arthritis Rheum. 2008 May;58(5):1539-45. doi: 10.1002/art.23450. Arthritis Rheum. 2008. PMID: 18438817 Free article.

5

Prognosis of Behcet's syndrome among men with mucocutaneous involvement at disease onset: long-term outcome of patients enrolled in a controlled trial.

Hamuryudan V, Hatemi G, Tascilar K, Sut N, Ozyazgan Y, Seyahi E, Mat C, Yurdakul S, Yazici H. Hamuryudan V, et al. Among authors: yazici h. Rheumatology (Oxford). 2010 Jan;49(1):173-7. doi: 10.1093/rheumatology/kep350. Rheumatology (Oxford). 2010. PMID: 19995858 Clinical Trial.

6

Behçet's syndrome.

Yazici Y, Yurdakul S, Yazici H. Yazici Y, et al. Among authors: yazici h. Curr Rheumatol Rep. 2010 Dec;12(6):429-35. doi: 10.1007/s11926-010-0132-z. Curr Rheumatol Rep. 2010. PMID: 20862570 Review.

7

An audit of Behcet's syndrome research: a 10-year survey.

Esen F, Schimmel EK, Yazici H, Yazici Y. Esen F, et al. Among authors: yazici h, yazici y. J Rheumatol. 2011 Jan;38(1):99-103. doi: 10.3899/jrheum.100335. Epub 2010 Oct 15. J Rheumatol. 2011. PMID: 20952472

8

Mortality bias in reporting cancer incidence in disease registries: comment on the article by Chen et al.

Yazici H, Tascilar K, Kiroglu G, Erar A, Duransoy ML. Yazici H, et al. Arthritis Rheum. 2011 Aug;63(8):2543-4; author reply 2544. doi: 10.1002/art.30447. Arthritis Rheum. 2011. PMID: 21567380 Free article. No abstract available.

9

Are we content that risk of cancer is not appreciably increased after tumor necrosis factor inhibitor use? Comment on the article by Solomon et al.

Yazici H, Yazici Y. Yazici H, et al. Among authors: yazici y. Arthritis Rheum. 2012 Jul;64(7):2414; author reply 2414-5. doi: 10.1002/art.34510. Arthritis Rheum. 2012. PMID: 22549846 Free article. No abstract available.

10

Quantiferon-TB Gold in tube assay for the screening of tuberculosis before and during treatment with tumor necrosis factor alpha antagonists.

Hatemi G, Melikoglu M, Ozbakir F, Tascilar K, Yazici H. Hatemi G, et al. Among authors: yazici h. Arthritis Res Ther. 2012 Jun 18;14(3):R147. doi: 10.1186/ar3882. Arthritis Res Ther. 2012. PMID: 22709461 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

669 results

Search Page

Filters